Johnson & Johnson has submitted a new drug application to the FDA for an implantable device developed by the Cima lab to make treating bladder cancer safer, more effective and less costly. The application follows promising clinical trial results, which showed an 83.5% complete response rate among patients, and earlier Breakthrough Designation status.